MTOR and ovarian cancer: Therefore, we aimed to evaluate the impact of such a correction method in the context of therapeutic response assessment of a dual Phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor (BEZ-235) on a chemoresistant model of human ovarian cancer xenografted in nude rats.